- Home
- PIII vs AXDX Comparison
PIII vs AXDX Comparison
Compare PIII & AXDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- AXDX
- Stock Information
- Founded
- PIII 2015
- AXDX 1982
- Country
- PIII United States
- AXDX United States
- Employees
- PIII N/A
- AXDX N/A
- Industry
- PIII Medical/Nursing Services
- AXDX Biotechnology: Laboratory Analytical Instruments
- Sector
- PIII Health Care
- AXDX Industrials
- Exchange
- PIII Nasdaq
- AXDX Nasdaq
- Market Cap
- PIII 30.8M
- AXDX 27.0M
- IPO Year
- PIII N/A
- AXDX 1996
- Fundamental
- Price
- PIII $0.18
- AXDX $0.71
- Analyst Decision
- PIII Hold
- AXDX Hold
- Analyst Count
- PIII 2
- AXDX 1
- Target Price
- PIII $0.25
- AXDX $1.00
- AVG Volume (30 Days)
- PIII 710.9K
- AXDX 49.1K
- Earning Date
- PIII 03-27-2025
- AXDX 03-21-2025
- Dividend Yield
- PIII N/A
- AXDX N/A
- EPS Growth
- PIII N/A
- AXDX N/A
- EPS
- PIII N/A
- AXDX N/A
- Revenue
- PIII $1,500,455,000.00
- AXDX $11,698,000.00
- Revenue This Year
- PIII $21.45
- AXDX $7.25
- Revenue Next Year
- PIII N/A
- AXDX N/A
- P/E Ratio
- PIII N/A
- AXDX N/A
- Revenue Growth
- PIII 18.48
- AXDX N/A
- 52 Week Low
- PIII $0.15
- AXDX $0.69
- 52 Week High
- PIII $0.89
- AXDX $2.09
- Technical
- Relative Strength Index (RSI)
- PIII 45.80
- AXDX 22.43
- Support Level
- PIII $0.16
- AXDX $0.69
- Resistance Level
- PIII $0.20
- AXDX $1.09
- Average True Range (ATR)
- PIII 0.02
- AXDX 0.11
- MACD
- PIII 0.00
- AXDX -0.04
- Stochastic Oscillator
- PIII 49.57
- AXDX 2.93
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About AXDX Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.